On day 3 of the 2022 Cholangiocarcinoma Foundation annual meeting, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma (CCA). She highlighted several areas that are “really exciting…potentially targetable, actionable, and in the works in terms of becoming available to our patients.”
Dr Shroff concluded: “There are many potential targets in biliary tract cancers; these rare alterations are crucial to find because we now have trials and we may soon have drugs available for these patients. So, comprehensive testing looking for fusions, looking for alterations, mutations, amplifications is going to be very important here.”
To sign up for our newsletter or print publications, please enter your contact information below.